Skip to main content

Table 1 Patient characteristics

From: MicroRNA-19a contributes to the epigenetic regulation of tissue factor in diabetes

Characteristics Low miR-19a High miR-19a p value
miR-19a 0.620 ± 0.07 4.537 ± 0.98 < 0.0001
miR-126 2.386 ± 0.31 13.26 ± 2.80 < 0.0001
Sex (m/f) 15/7 18/4 n.s.
Age (years) 67 ± 1.7 62 ± 1.9 < 0.05
History of stroke (%) 13.6 9.0 n.s.
History of MI (%) 18.1 4.5 n.s.
CAD (%) 50.0 31.8 n.s.
Hypertension (%) 100 100 n.s.
PAD (%) 27.2 22.7 n.s.
Diabetic neuropathy (%) 81.8 77.2 n.s.
Diabetes years 15 ± 2.3 11 ± 2.1 n.s.
BMI (kg/m2) 30.2 ± 1.3 34.2 ± 1.7 n.s.
CRP (mg/dL) 0.83 ± 0.2 1.0 ± 0.5 n.s.
HbA1c (%) 7.7 ± 0.2 8.7 ± 0.3 n.s.
HbA1c (mmol/mol) 61.1 ± 3.1 72.3 ± 3.9 n.s.
Fasting blood glucose (mg/dL) 144 ± 12 146 ± 6 n.s.
ACE-inhibitor (%) 40.9 50.0 n.s.
AT II antagonist (%) 31.8 31.8 n.s.
Diuretics (%) 54.5 72.7 n.s.
Statins (%) 54.5 50.0 n.s.
Anti-diabetic drugs: insulin (%) 72.7 68.1 n.s.
Metformin (%) 36.3 68.1 < 0.05
Sulfonylureas (%) 27.2 4.5 < 0.05
Acarbose (%) 13.0 9.0 n.s.
Glinides (%) 4.5 13.6 n.s.
  1. ACE angiotensin-converting enzyme, AT II angiotensin II, BMI body mass index, CAD coronary artery disease, CRP c-reactive protein, HbA1c glycated haemoglobin, MI myocardial infarction, PAD peripheral artery disease